Evidence Grade A — Regulatory approved. 28989 published studies. 912 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Oxytocin (sold as Pitocin) is a synthetic version of the naturally occurring "love hormone" — produced in the brain and involved in childbirth, breastfeeding, and social bonding. In hospitals, it is one of the most commonly used medications in obstetrics: given intravenously to induce or strengthen labour contractions and to prevent dangerous bleeding after delivery. It is on the WHO's List of Essential Medicines.
Oxytocin is also known by these brand and alternate names:
28,989 published studies: 13988 human, 11568 animal, 2052 in-vitro, 3942 reviews
Oxytocin (as Pitocin) is used worldwide for labour induction, labour augmentation, and prevention of postpartum haemorrhage. It requires careful intravenous dose titration because excessive stimulation can cause dangerously strong contractions.
Beyond obstetrics, oxytocin has been the subject of extensive research into its behavioural and psychological effects, including studies in autism spectrum disorder, anxiety, post-traumatic stress disorder, and social cognition. However, intranasal oxytocin for behavioural applications remains experimental, and results from clinical trials have been mixed. The WHO lists injectable oxytocin as an essential medicine, and its availability and proper storage (requiring refrigeration) are significant public health concerns in low-resource settings.
Oxytocin targets specific receptors on the smooth muscle of the uterus, triggering powerful rhythmic contractions. During pregnancy, the number of these receptors increases dramatically (up to 300-fold by term), which is why the uterus becomes increasingly sensitive to oxytocin as pregnancy progresses. Oxytocin also acts on muscle cells in the breast to trigger the 'let-down' reflex during breastfeeding. Beyond these reproductive roles, oxytocin acts in the brain to influence social bonding, trust, and emotional responses, earning it the popular label of the 'love hormone.'
Oxytocin's role in obstetric practice is well established with decades of clinical experience. The WHO recommends it as the preferred drug for preventing postpartum haemorrhage — the leading cause of maternal death worldwide. Safe use requires careful dose titration because excessive stimulation can cause dangerously strong contractions. Beyond obstetrics, there has been extensive research into intranasal oxytocin for behavioural and neuropsychiatric conditions — autism, social anxiety, PTSD, and trust-related disorders. Results have been largely disappointing: a major 2021 trial for autism was negative, and meta-analyses show no consistent benefit. Safety concerns with high doses include water retention and dangerously low sodium levels (due to structural similarity to vasopressin). Proper storage requiring refrigeration remains a significant public health challenge in low-resource settings where postpartum haemorrhage is most common.
PeptideTrace tracks 912 registered clinical trials for Oxytocin sourced from ClinicalTrials.gov.
Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)
Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
3-hour Versus 12-hour Double-balloon Catheter for Labor Induction
Reducing Self-Dehumanization to Examine Oxytocin and Suicide Risk
Is Nipple Stimulation Effective for Inducing Labor and Acceptable to Patients, Nurses, and Providers?
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 1
FDA SUPPL 13
FDA SUPPL 14
FDA SUPPL 2
FDA SUPPL 16
FDA SUPPL 15
FDA SUPPL 3
FDA SUPPL 17
FDA SUPPL 4
FDA SUPPL 18
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 6
FDA SUPPL 7
FDA SUPPL 23
FDA SUPPL 20
FDA SUPPL 22
FDA SUPPL 9
Health Canada Market Authorisation
FDA SUPPL 12
FDA SUPPL 11
FDA SUPPL 24
FDA SUPPL 19
FDA SUPPL 13
FDA SUPPL 26
FDA SUPPL 25
FDA SUPPL 14
FDA SUPPL 15
FDA SUPPL 16
FDA SUPPL 27
FDA SUPPL 28
FDA SUPPL 17
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 18
FDA SUPPL 22
FDA SUPPL 21
FDA SUPPL 23
FDA SUPPL 28
FDA SUPPL 34
FDA ORIG 1
FDA SUPPL 32
FDA SUPPL 42
FDA SUPPL 31
FDA SUPPL 33
FDA SUPPL 41
FDA SUPPL 49
Oxytocin is a 9-amino-acid cyclic neuropeptide with a Cys1-Cys6 intramolecular disulfide bridge and a C-terminal amidation. It is produced in the hypothalamic paraventricular and supraoptic nuclei and released from the posterior pituitary. Its half-life is approximately 3–5 minutes intravenously.
Oxytocin binds the oxytocin receptor (OXTR), a Gq/11-coupled GPCR. Activation triggers the PLC/IP3/DAG pathway → intracellular calcium release → myometrial smooth muscle contraction (uterus) and myoepithelial cell contraction (mammary gland for milk ejection). OXTR expression in the myometrium increases dramatically during pregnancy (upregulated by estrogen), making the uterus progressively more sensitive to oxytocin near term.
Oxytocin is marketed as Pitocin (synthetic oxytocin injection) for labor induction and augmentation, and management of postpartum hemorrhage. It is one of the most commonly used medications in obstetrics worldwide. Administered intravenously with careful dose titration to achieve adequate uterine contractions (typically 3–5 per 10 minutes) without hyperstimulation.
Compare prices from 11 vendor listings
View pricing data across vendors and countries for Oxytocin
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Comparisons
Timelines
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
